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Abstract
Purpose Because we had observed in the synovial sarcoma subgroup of a broad phase III advanced soft tissue sarcoma study a
significantly greater objective regression rate from ifosfamideþdoxorubicin (88%) than from doxorubicin alone (20%)
(P¼0.02), the Eastern Cooperative Oncology Group (ECOG) decided to further assess this two drug combination in a
subsequent Phase II study.
Patients Between 1994 and 1999, twelve adult patients with advanced synovial sarcomas were enrolled to receive, as their
initial chemotherapy, ifosfamide 7.5gm/m
2 plus doxorubicin 60mg/m
2, given intravenously over two consecutive days every
3 weeks.
Methods Each day for 2 days doxorubicin 30mg/m
2 was infused over 5min through a running i.v., followed by ifosfamide
3750mg/m
2 over 4h. Continuous i.v. fluid was infused at 300mL/h for 3h on day 1, before chemotherapy was begun; then
the infusion was continued at 100mL/h for a total of 3 days. Mesna 750mg/m
2 was given 15min before ifosfamide and at
4 and 8h after ifosfamide on days 1 and 2 of each treatment cycle. Filgrastim (G-CSF) 5mg/kg was given subcutaneously
each day for 14 days beginning on day 3 of each treatment cycle to limit the severity of neutropenia.
Results Five of our 12 patients (42%) experienced partial regression of their advanced synovial sarcomas; however, this first
stage result was borderline for proceeding to the second planned stage of accrual and our case accrual was quite poor. Thus,
the study was closed after stage one accrual. Our patients received a median of four cycles of chemotherapy (range: 1 to 6).
All patients experienced at least grade 3 neutropenia (grade 4 in nine of them), and one patient died of treatment-related
sepsis following the initial cycle of chemotherapy. Median survival was 11 months.
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Introduction
Among the soft tissue sarcomas synovial sarcoma
is reported to be one of the more responsive to
systemic chemotherapy.
1,2 Analysis of the small
synovial sarcoma subgroup within a phase III study
by ECOG appeared to support this thesis for only the
combination of ifosfamide and doxorubicin, as
compared with doxorubicin alone.
3 In that explora-
tory subgroup analysis the two-drug regimen with an
objective regression rate of 88% appeared signifi-
cantly better (P¼0.02) than doxorubicin alone
(20%). We suspected that this result might be
youth related. Our present phase II study was
designed to better assess that remarkably high
tumor regression rate in advanced synovial sarcoma
patients receiving ifosfamide plus doxorubicin.
Patients
Patients at least 15 years old with histologically
confirmed synovial sarcoma were enrolled if they had
residual, recurrent or metastatic disease measurable
by physical examination, X-rays, CT scanning or
MRI. All patients had ECOG performance status
ratings of 0, 1, or 2. Satisfactory bone marrow
function, renal function, and hepatic function were
recognized, respectively by baseline leukocyte counts
of  4000/mL, platelet counts of  125000/mL, and
hematocrit of  28%; serum creatinine  1.5mg/dL;
and serum bilirubin of  2mg/dL. The patients were
free of significant infection or other serious illness
that might be aggravated by this chemotherapy.
None of the patients had previously received cancer
chemotherapy, and no previously irradiated lesion
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least 25% since radiotherapy. Pregnant or lactating
patients also were excluded.
Methods
Combination ifosfamide and doxorubicin was begun
by i.v. infusion after the infusion had been running
at 300mL/h for 3h. Doxorubicin 30mg/m
2 was
infused over 5min on day 1, followed by ifosfamide
3750mg/m
2 over 4h. The continuous i.v. infusion
was then slowed to 100mL/h for the remainder of
the planned 3 days of fluid supplementation. Mesna
750mg/m
2 was infused i.v. over 15min before
ifosfamide and repeated 4 and 8h later. Day 2
chemotherapy was identical to day 1 treatment.
Filgrastim 5mg/kg was given s.c. daily for 14 days
beginning the day following completion of chemo-
therapy. This chemotherapy regimen (supported by
3 days of i.v. fluids) was repeated every 3 weeks until
disease progression occurred or until maximum
tolerable doses of doxorubicin were reached
(500mg/m
2).
Standard objective response criteria were used for
therapeutic assessment, and NCI Common Toxicity
Criteria were used to assess drug toxicity. Our plan
to better define the objective regression rate of
ifosfamide plus doxorubicin in patients with
advanced synovial sarcoma involved a two-stage
design. If at least five of the first 12 patients
experienced tumor regression, a 38-patient second
stage of accrual would begin. With 50 patients the
study would permit estimation of the true response
rate with a 95% confidence limit of  14%.
Results
Our patients received a median of four cycles of
chemotherapy (range: 1–6).
Despite the use of filgrastim for 2 weeks after each
2-day ifosfamideþdoxorubicin treatment, neutro-
penia reached grade 3 in all 12 patients (grade 4 in
nine of them); and one patient died of treatment
related sepsis following the initial cycle of chemo-
therapy. Except for myelosuppression, no severe drug
toxicity has been observed. Five of the 12 patients
(42%) experienced objective partial tumor regres-
sion; however, the borderline result data for proceed-
ing and the poor case accrual led us to close the study
after completing stage one. With two patients still
alive, survival has ranged from 1 to 71þ months
(median 11 months).
Discussion
By the time our study began in 1994 the previous
Phase III E.C.O.G. study
3 and several others had
established ifosfamide plus doxorubicin as a ‘stan-
dard’ regimen for soft tissue sarcomas. Perhaps the
sluggish case accrual experienced in the current study
was in part a result of the ready access of patients to
off-study treatment with this regimen.
As discussed in our 1993 report, the observed
objective regression in seven of the eight patients
with advanced synovial sarcomas who received this
ifosfamideþdoxorubicin regimen appeared to be
youth related
3. Because of the small number of
patients in the present study, as in the previous one,
no better understanding of this suspected youth-
related responsiveness is forthcoming from these
results. Median age of the synovial sarcoma patients
in the present report was 44 years (range, 26–78),
while those receiving this regimen in our 1993 report
had a median age of 56 years (range, 37–78), as
compared with 61 years (range, 50–74) for the 1993
patients receiving doxorubicin alone.
Remarkably all 13 patients receiving high-dose
ifosfamide experienced objective tumor regression in
another phase II trial reported by Rosen et al.
4 All of
their patients (median 28 years) were under 40 years
of age, the break point shown to segregate chemo-
therapy responsiveness by age in our broad soft tissue
sarcoma report from 1993.
3 Using vincristine,
dactinomycin, dacarbazine, doxorubicin, and cyclo-
phosphamide in various combination regimens
from the tradition of children’s cancer trials with-
out ifosfamide, Pappo et al. reported that their
five metastatic synovial sarcoma patients all ‘fared
poorly’ despite their youth (all under 21 years
of age).
5
In a retrospective analysis of prognostic factors
involving 112 patients with primary localized syno-
vial sarcomas from Memorial Sloan-Kettering
Cancer Center, Lewis et al. identified a survival
trend (P¼0.07) favoring patients under 40 years of
age.
6 Another multicenter study of that type includ-
ing 128 patients from France failed to identify any
age-related survival advantage when synovial sar-
coma patients above and below age 33 years were
compared.
7
Finally the detailed European Organization for
Research and Treatment of Cancer (EORTC)
analysis of prognostic factors affecting the outcome
of advanced soft tissue sarcoma patients identified
youth as favorable for chemotherapy responsiveness
(P¼0.001) in general. The synovial sarcoma subset,
however, were not more responsive, if age-matched,
than the overall group.
8 These results suggest that
the apparently greater chemotherapy responsiveness
attributed to synovial sarcomas may be simply due to
their occurrence generally in younger patients. The
EORTC patients with synovial sarcoma also had
significantly better survival than most of the other
histological types, a fact the authors attributed at
least in part to their relative youth.
Recent genetic studies in synovial sarcoma suggest
a strong association between the type of transloca-
tional gene fusion and histological type (monophasic
10 Edmonson et al.or biphasic), with better prognosis seen in the
SYT-SSX2 tumors, which tend to be monophasic.
9
Perhaps further genetic studies may in the future
permit the development of genetically specific
molecular therapy to control the aberrant genetic
focus found to be driving the growth of an individual
synovial sarcoma. Proof of principle for treatment of
this type already is available in the case of imatinib
mesylate (STI-571) in gastrointestinal stromal sar-
comas (GIST).
10
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